source
- Overlooked drugs can gain value when markets evolve, says Azurity CEORon Scarboro, chief executive of Azurity Pharmaceuticals, wrote about how medicines that seemed unsuccessful can become valuable when market conditions change. He argues that the industry often co…
- Australian clinical trials attract more U.S. sponsors amid regulatory uncertaintyCROs are reporting faster startup timelines, predictable regulation, and tax incentives as reasons for increasing interest in conducting clinical trials in Australia. State-level incentives in Que…